Stopping a GLP-1: what happens to your weight
Reviewed 9 sourcesPublished by PepVault
What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

- Last reviewed
- Sources
- 9
- Questions
- 7
- Compounds
- 2
The short answer
In the trials, most lost weight returned within a year of stopping. A year after semaglutide ended in STEP 1, people had regained about two-thirds of their loss. In SURMOUNT-4, people switched from tirzepatide to placebo gained 14% of their weight at the switch, ending 9.9% below where they started. Blood pressure and blood sugar followed. Staying on the drug kept it off; plan any stop with your prescriber.
Evidence: Randomised trials in people (the STEP 1 off-treatment extension, whose analyses were exploratory, the STEP 4 and SURMOUNT-4 withdrawal trials, and a liraglutide and exercise trial with a year of post-treatment follow-up), a 2026 BMJ meta-analysis of 37 studies, and the FDA labels for Wegovy and Zepbound.

How much weight comes back after stopping a GLP-1?
Three trials stopped the drug on purpose and kept weighing people. In the STEP 1 extension, everyone stopped semaglutide 2.4 mg (a Wegovy maintenance dose) after 68 weeks and was followed for one more year1. STEP 4 and SURMOUNT-4 used a withdrawal design: everyone took the drug first, then some were switched, without knowing it, to placebo injections (a third in STEP 4, half in SURMOUNT-4), a dummy shot with no drug in it24. A 2026 BMJ meta-analysis, a study that pools the results of many trials, then put the numbers together6.
| Trial | Weeks on the drug | Weeks after stopping | Weight at the stop | What came back |
|---|---|---|---|---|
| STEP 1 extension, semaglutide 2.4 mg | 68 | 52 | Down 17.3% | 11.6 percentage points of the starting weight regained by week 120, leaving people 5.6% below their starting weight1. |
| STEP 4, semaglutide 2.4 mg | 20 | 48 | Down 10.6% | Up 6.9% from the weight at the switch to placebo (week 20), not from the start2; 5.4% below the starting weight at week 68, against 17.7% for those who stayed on it3. |
| SURMOUNT-4, tirzepatide 10 or 15 mg | 36 | 52 | Down 20.9% | Up 14.0% from the weight at the switch to placebo (week 36), not from the start; 9.9% below the starting weight at week 88, against 25.3% for those who stayed on it4. |
| BMJ meta-analysis, semaglutide and tirzepatide arms | Varied | Varied | Down 14.7 kg on average | About 9.9 kg regained in the first year, by the review's model; a return to the starting weight projected at about 1.5 years6. |

Two differences matter when reading the rows. In the STEP 1 extension the diet and activity programme stopped along with the drug1, while STEP 4 and SURMOUNT-4 kept the lifestyle counselling going in both groups24. And the starting points differ: STEP 4 stopped after a shorter run and a smaller loss, and the STEP 1 authors link their faster regain to the bigger loss before the stop1.

PepVault for iPhone
Keep your protocol in PepVault
PepVault's weight log keeps every weigh-in on one chart whether or not a protocol is running, and a finished protocol stays under Past protocols with its start and end dates, so the months after your last dose sit on the same curve as the months on it.
7 days free on the yearly plan for new subscribers.
Why does the weight come back?
Because the drug was doing the work. GLP-1 is one of the body's own regulators of appetite and of how much is eaten, and its receptor sits in the brain areas that set appetite; semaglutide and tirzepatide switch that receptor on, and the labels put the drop in calorie intake down to their effect on appetite89. That effect lasts as long as the drug is in the blood. As the drug leaves, the effect fades, and in every trial here the weight followed124.
It leaves slowly. Semaglutide's half-life, the time for the blood level to fall by half, is about one week, so it stays in circulation for about 5 to 7 weeks after the last injection8. Tirzepatide's half-life is about 5 days, 5 to 6 in people with overweight or obesity9. The chart shows the build-up on weekly doses; the same one-week half-life that makes the climb gradual makes the fall gradual.
Try it
How Semaglutide builds up
An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.
The STEP 1 authors read their result as a sign that obesity is a chronic condition, and that ongoing treatment is needed to keep the improvements1. The labels say the same in their own words: both drugs are approved to reduce excess weight and to maintain that reduction long term89.
How fast does the weight come back?
Steadily, over the first year. In the STEP 1 extension the regain was still going at week 120, though the average curve was slowing towards the end; whether it would have levelled off below the starting weight needs longer follow-up to tell1. The BMJ meta-analysis puts the pace after semaglutide or tirzepatide at about 0.8 kg a month, twice the 0.4 kg a month averaged across all weight medicines. Even that average was faster than the regain after diet and behaviour programmes6.
Bigger losses tended to bring bigger regains, but also kept more. In the STEP 1 extension, people who had lost 20% or more during treatment still ended the year 12.1% below their starting weight1. Overall, 48.2% of the semaglutide group were still at least 5% below their starting weight a year after stopping1.
How do you keep track of the months after the last dose?
The trials could see all this because they kept measuring after the drug stopped. The same habits make the change visible for anyone, on or off a drug:
- Weigh in on the same day of the week, at the same time, so the trend means something.
- Bring the curve and the lab results to the prescriber; any decision about continuing, changing or stopping is theirs to make with you.
PepVault's weight log keeps every weigh-in on one chart whether or not a protocol is running, and a finished protocol stays under Past protocols with its start and end dates, so the months after your last dose sit on the same curve as the months on it. Track your weight in PepVault
PepVault's body check-ins record the waist, and its bloodwork log takes HbA1c, LDL, triglycerides and hs-CRP, the kinds of markers these trials followed. Track your weight in PepVault
Do blood pressure and blood sugar change after stopping?
Yes, they drift back with the weight. In the STEP 1 extension, average systolic blood pressure (the top number) in the semaglutide group went from 129 mmHg at the start to 121 at the end of treatment, then to 131 a year after stopping. HbA1c, the three-month average of blood sugar, went from 5.7% to 5.2% and back to 5.6%1. Of the people who had prediabetes at the start, 93.6% were in the normal range at the end of treatment and 43.3% a year later, against 34.0% in the placebo group1.
Not everything went all the way back. C-reactive protein, a blood marker of inflammation, and several blood fats stayed better than in the placebo group at week 1201. In SURMOUNT-4, systolic blood pressure rose 8.4 points over the year after the switch to placebo, against 2.1 points on tirzepatide, counting only data from while people were taking their assigned injections5. Across all weight medicines, the BMJ meta-analysis projected every cardiometabolic marker it tracked back at its starting level within about 1.4 years of stopping; it had too little data to run that analysis for semaglutide and tirzepatide alone6.
What did the trials try to keep the weight off?
Mostly, staying on the drug. In STEP 4, people who kept taking semaglutide lost a further 7.9% over 48 weeks while the placebo group gained 6.9%, both counted from the week-20 weight2. In SURMOUNT-4, those who kept taking tirzepatide lost a further 5.5% from the week-36 weight, and 89.5% of them held on to at least 80% of what they had lost, against 16.6% of the placebo group4. Lifestyle counselling alone, which both placebo groups kept receiving, did not stop the regain24.
One trial tested exercise and kept measuring after a GLP-1 was stopped. In this Copenhagen trial that began after an 8-week low-calorie diet, people randomised to liraglutide (a daily GLP-1 drug), supervised exercise, both or placebo were followed for a year after treatment ended. Those who had done a year of supervised exercise kept their weight and body composition a year after the programme ended, while those who had taken liraglutide alone regained 6.0 kg more over that year than the exercise group7. People who had done both kept 5.1 kg more off than those on liraglutide alone7.
What the trials did not test, so there is no trial number for it:
- Tapering, a gradual step-down of the dose before stopping: in STEP 1 the drug stopped at once, and in STEP 4 and SURMOUNT-4 it was swapped straight for placebo124.
- A lower maintenance dose: STEP 4 continued 2.4 mg, and SURMOUNT-4 allowed no dose changes after the switch24.
- Structured training with semaglutide or tirzepatide: the one exercise trial here used liraglutide7, and the SURMOUNT-4 authors note their trial did not test intensive behavioural therapy4.
- How much of the regain was fat and how much was lean mass: the semaglutide and tirzepatide trials here weighed people but did not report body composition after the stop124.
- What happens after the first year off the drug: follow-up ended about a year after the stop124.
Commonly reported: hunger and "food noise" coming back within a few weeks of the last injection rather than overnight; the scale creeping up slowly at first; and some people stepping the dose down before stopping, or settling on a lower long-term dose with their prescriber, a pattern none of these trials studied.
What do the labels say about stopping or missing doses?
Neither label sets out a stopping schedule. Wegovy's label does give a rule for missed injections, in this order8:
- Check how far away your next scheduled dose is.
- If it is more than 2 days (48 hours) away, the label says to take the missed dose as soon as possible.
- If it is less than 2 days away, the label says to skip the missed dose and take your next one on the usual day.
- If you have missed two or more weekly doses in a row, contact your prescriber before the next one: the label has them restart the dose climb at a lower dose, to lower the risk of stomach side effects.
Zepbound's rule is a 4-day window: take a missed dose within 4 days (96 hours); after more than 4 days, skip it and go back to the usual day. The injection day can move, as long as doses stay at least 3 days apart9. One stopping rule does exist: Wegovy's label advises stopping it at least 2 months before a planned pregnancy, because of semaglutide's long half-life8.
These are the labels' rules and the trials' averages, not a plan for stopping, restarting or changing any one person's dose. Talk to your prescriber before you stop or restart, and sooner if you plan a pregnancy or have missed two or more weekly doses.
Sources
- Wilding JPH et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PubMed 35441470
- Rubino D et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. PubMed 33755728
- ClinicalTrials.gov NCT03548987. Research study investigating how well semaglutide works in people suffering from overweight or obesity (STEP 4; sponsor Novo Nordisk A/S). Results record. clinicaltrials.gov
- Aronne LJ et al.; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. PubMed 38078870
- ClinicalTrials.gov NCT04660643. A study of tirzepatide (LY3298176) in participants with obesity or overweight for the maintenance of weight loss (SURMOUNT-4; sponsor Eli Lilly and Company). Results record. clinicaltrials.gov
- West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026. PubMed 41500720
- Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024. PubMed 38544798
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, revised June 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.